EvergreenHealth

Running trials

• Recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  NCT07589595· Phase 2· Source

• Recruiting

  Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07095465· Phase 3· Source

• Recruiting

  Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07029581· Phase 2· Source

• Recruiting

  A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

  NCT06680830· Phase 2· Source

• Active, not recruiting

  A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

  NCT05399888· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lewy body dementia3 recruiting
• Alzheimer disease1 recruiting
• Parkinson disease1 recruiting

Researchers

No researcher is linked here yet.